Novartis Reports High Operating Margins Following Innovative Drugs Pivot
Novartis AG reported a significant transformation into a high-margin innovative medicines company in early 2026 following the successful…
Lilly raises stakes in Novartis battle with Verzenio data
Armed with new survival data from the monarchE trial of CDK4/6 inhibitor Verzenio, Eli Lilly looks set to…